LRMR Quote, Financials, Valuation and Earnings

Gossamer Bio, Inc. has a net margin of -- compared to Larimar Therapeutics, Inc.'s net margin of -342.33%. Larimar Therapeutics, Inc.'s return on equity of -126.84% beat Gossamer Bio, Inc.'s return on equity of -615%.

Larimar Therapeutics, Inc. has a consensus price target of $16.70, signalling upside risk potential of 248.64%. On the other hand Gossamer Bio, Inc. has an analysts' consensus of $3.69 which suggests that it could grow by 896.14%. Given that Gossamer Bio, Inc. has higher upside potential than Larimar Therapeutics, Inc., analysts believe Gossamer Bio, Inc. is more attractive than Larimar Therapeutics, Inc..

Larimar Therapeutics, Inc. has a beta of 1.019, which suggesting that the stock is 1.867% more volatile than S&P 500. In comparison Gossamer Bio, Inc. has a beta of 2.159, suggesting its more volatile than the S&P 500 by 115.854%.

Larimar Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gossamer Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Larimar Therapeutics, Inc. pays -- of its earnings as a dividend. Gossamer Bio, Inc. pays out -- of its earnings as a dividend.

Larimar Therapeutics, Inc. quarterly revenues are --, which are smaller than Gossamer Bio, Inc. quarterly revenues of $13.8M. Larimar Therapeutics, Inc.'s net income of -$62.5M is lower than Gossamer Bio, Inc.'s net income of -$47.2M. Notably, Larimar Therapeutics, Inc.'s price-to-earnings ratio is -- while Gossamer Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Larimar Therapeutics, Inc. is -- versus 1.73x for Gossamer Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

ImmunityBio, Inc. has a net margin of -- compared to Larimar Therapeutics, Inc.'s net margin of -161.83%. Larimar Therapeutics, Inc.'s return on equity of -126.84% beat ImmunityBio, Inc.'s return on equity of --.

Larimar Therapeutics, Inc. has a consensus price target of $16.70, signalling upside risk potential of 248.64%. On the other hand ImmunityBio, Inc. has an analysts' consensus of $14.80 which suggests that it could grow by 102.74%. Given that Larimar Therapeutics, Inc. has higher upside potential than ImmunityBio, Inc., analysts believe Larimar Therapeutics, Inc. is more attractive than ImmunityBio, Inc..

Larimar Therapeutics, Inc. has a beta of 1.019, which suggesting that the stock is 1.867% more volatile than S&P 500. In comparison ImmunityBio, Inc. has a beta of 0.047, suggesting its less volatile than the S&P 500 by 95.312%.

Larimar Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ImmunityBio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Larimar Therapeutics, Inc. pays -- of its earnings as a dividend. ImmunityBio, Inc. pays out -- of its earnings as a dividend.

Larimar Therapeutics, Inc. quarterly revenues are --, which are smaller than ImmunityBio, Inc. quarterly revenues of $38.3M. Larimar Therapeutics, Inc.'s net income of -$62.5M is lower than ImmunityBio, Inc.'s net income of -$62M. Notably, Larimar Therapeutics, Inc.'s price-to-earnings ratio is -- while ImmunityBio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Larimar Therapeutics, Inc. is -- versus 60.49x for ImmunityBio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Iovance Biotherapeutics, Inc. has a net margin of -- compared to Larimar Therapeutics, Inc.'s net margin of -82.92%. Larimar Therapeutics, Inc.'s return on equity of -126.84% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.64%.

Larimar Therapeutics, Inc. has a consensus price target of $16.70, signalling upside risk potential of 248.64%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 162.39%. Given that Larimar Therapeutics, Inc. has higher upside potential than Iovance Biotherapeutics, Inc., analysts believe Larimar Therapeutics, Inc. is more attractive than Iovance Biotherapeutics, Inc..

Larimar Therapeutics, Inc. has a beta of 1.019, which suggesting that the stock is 1.867% more volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.765, suggesting its less volatile than the S&P 500 by 23.49%.

Larimar Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Larimar Therapeutics, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Larimar Therapeutics, Inc. quarterly revenues are --, which are smaller than Iovance Biotherapeutics, Inc. quarterly revenues of $86.7M. Larimar Therapeutics, Inc.'s net income of -$62.5M is higher than Iovance Biotherapeutics, Inc.'s net income of -$71.9M. Notably, Larimar Therapeutics, Inc.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Larimar Therapeutics, Inc. is -- versus 4.62x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vir Biotechnology, Inc. has a net margin of -- compared to Larimar Therapeutics, Inc.'s net margin of -66.99%. Larimar Therapeutics, Inc.'s return on equity of -126.84% beat Vir Biotechnology, Inc.'s return on equity of -46.56%.

Larimar Therapeutics, Inc. has a consensus price target of $16.70, signalling upside risk potential of 248.64%. On the other hand Vir Biotechnology, Inc. has an analysts' consensus of $20.78 which suggests that it could grow by 129.34%. Given that Larimar Therapeutics, Inc. has higher upside potential than Vir Biotechnology, Inc., analysts believe Larimar Therapeutics, Inc. is more attractive than Vir Biotechnology, Inc..

Larimar Therapeutics, Inc. has a beta of 1.019, which suggesting that the stock is 1.867% more volatile than S&P 500. In comparison Vir Biotechnology, Inc. has a beta of 1.658, suggesting its more volatile than the S&P 500 by 65.789%.

Larimar Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vir Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Larimar Therapeutics, Inc. pays -- of its earnings as a dividend. Vir Biotechnology, Inc. pays out -- of its earnings as a dividend.

Larimar Therapeutics, Inc. quarterly revenues are --, which are smaller than Vir Biotechnology, Inc. quarterly revenues of $64.1M. Larimar Therapeutics, Inc.'s net income of -$62.5M is lower than Vir Biotechnology, Inc.'s net income of -$42.9M. Notably, Larimar Therapeutics, Inc.'s price-to-earnings ratio is -- while Vir Biotechnology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Larimar Therapeutics, Inc. is -- versus 18.36x for Vir Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.